SG10202112960QA - Mavacamten for use in the treatment of hypertrophic cardiomyopathy - Google Patents
Mavacamten for use in the treatment of hypertrophic cardiomyopathyInfo
- Publication number
- SG10202112960QA SG10202112960QA SG10202112960QA SG10202112960QA SG10202112960QA SG 10202112960Q A SG10202112960Q A SG 10202112960QA SG 10202112960Q A SG10202112960Q A SG 10202112960QA SG 10202112960Q A SG10202112960Q A SG 10202112960QA SG 10202112960Q A SG10202112960Q A SG 10202112960QA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- individual
- daily dose
- blood plasma
- plasma concentration
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541591P | 2017-08-04 | 2017-08-04 | |
| US201762584537P | 2017-11-10 | 2017-11-10 | |
| US201862639922P | 2018-03-07 | 2018-03-07 | |
| US201862671585P | 2018-05-15 | 2018-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202112960QA true SG10202112960QA (en) | 2021-12-30 |
Family
ID=63350605
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202112960QA SG10202112960QA (en) | 2017-08-04 | 2018-08-03 | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
| SG11202000549TA SG11202000549TA (en) | 2017-08-04 | 2018-08-03 | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000549TA SG11202000549TA (en) | 2017-08-04 | 2018-08-03 | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US20200054636A1 (https=) |
| EP (2) | EP3661514B1 (https=) |
| JP (3) | JP2020529996A (https=) |
| KR (2) | KR20200035973A (https=) |
| CN (2) | CN111182901A (https=) |
| AU (2) | AU2018311974B2 (https=) |
| CA (1) | CA3071948A1 (https=) |
| DK (1) | DK3661514T3 (https=) |
| ES (1) | ES3055679T3 (https=) |
| FI (1) | FI3661514T3 (https=) |
| HR (1) | HRP20251598T1 (https=) |
| HU (1) | HUE073047T2 (https=) |
| IL (2) | IL322175A (https=) |
| LT (1) | LT3661514T (https=) |
| MA (1) | MA49760B1 (https=) |
| MX (3) | MX2020001406A (https=) |
| MY (1) | MY208231A (https=) |
| PL (1) | PL3661514T3 (https=) |
| PT (1) | PT3661514T (https=) |
| RS (1) | RS67534B1 (https=) |
| RU (1) | RU2020109345A (https=) |
| SG (2) | SG10202112960QA (https=) |
| SI (1) | SI3661514T1 (https=) |
| SM (1) | SMT202500413T1 (https=) |
| TW (1) | TWI907332B (https=) |
| UA (1) | UA130213C2 (https=) |
| UY (1) | UY37834A (https=) |
| WO (1) | WO2019028360A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| WO2020257609A1 (en) * | 2019-06-21 | 2020-12-24 | MyoKardia, Inc. | Diagnostics and treatments for cardiac disease |
| CN110698415B (zh) * | 2019-10-21 | 2023-05-09 | 上海先行医药开发有限公司 | 一种肌球蛋白抑制剂及其制备方法和用途 |
| EP4054588A4 (en) * | 2019-11-10 | 2023-12-13 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| HUE069154T2 (hu) * | 2020-01-28 | 2025-02-28 | Assia Chem Ind Ltd | A mavakamten szilárd állapotú formái és eljárás elõállításukra |
| MX2023002024A (es) * | 2020-08-28 | 2023-05-10 | Myokardia Inc | Métodos de tratamiento con modulador de miosina. |
| WO2022105852A1 (zh) | 2020-11-20 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| US20240082248A1 (en) * | 2021-02-01 | 2024-03-14 | Dr. Reddy's Laboratories Limited | Process for preparation of mavacamten and solid state forms thereof |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| CN112939876A (zh) * | 2021-03-10 | 2021-06-11 | 杭州科巢生物科技有限公司 | Mavacamten的晶型I及其制备方法 |
| WO2022189599A1 (en) | 2021-03-12 | 2022-09-15 | Sandoz Ag | Crystalline forms of mavacamten for the treatment of hcm |
| PT4370116T (pt) * | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| US20240389972A1 (en) * | 2021-09-24 | 2024-11-28 | Koninklijke Philips N.V. | METHODS AND SYSTEMS FOR GENERATING LIKELIHOOD OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) |
| JP2025534288A (ja) | 2022-09-26 | 2025-10-15 | エッジワイズ セラピューティクス， インコーポレイテッド | １，４－ジヒドロキナゾリノン化合物およびその使用 |
| WO2024097284A1 (en) * | 2022-11-02 | 2024-05-10 | MyoKardia, Inc. | Mavacamten and derivatives thereof for use in treating atrial dysfunction |
| EP4688756A1 (en) | 2023-03-27 | 2026-02-11 | Edgewise Therapeutics, Inc. | Quinazoline dione compounds and uses thereof |
| WO2024206339A1 (en) | 2023-03-27 | 2024-10-03 | Edgewise Therapeutics, Inc. | Quinolinone amide compounds and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000071T1 (it) * | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
-
2018
- 2018-08-03 CA CA3071948A patent/CA3071948A1/en active Pending
- 2018-08-03 RU RU2020109345A patent/RU2020109345A/ru unknown
- 2018-08-03 KR KR1020207004507A patent/KR20200035973A/ko not_active Ceased
- 2018-08-03 EP EP18759209.2A patent/EP3661514B1/en active Active
- 2018-08-03 PL PL18759209.2T patent/PL3661514T3/pl unknown
- 2018-08-03 MA MA49760A patent/MA49760B1/fr unknown
- 2018-08-03 HR HRP20251598TT patent/HRP20251598T1/hr unknown
- 2018-08-03 RS RS20251281A patent/RS67534B1/sr unknown
- 2018-08-03 LT LTEPPCT/US2018/045180T patent/LT3661514T/lt unknown
- 2018-08-03 UA UAA202001501A patent/UA130213C2/uk unknown
- 2018-08-03 SG SG10202112960QA patent/SG10202112960QA/en unknown
- 2018-08-03 PT PT187592092T patent/PT3661514T/pt unknown
- 2018-08-03 ES ES18759209T patent/ES3055679T3/es active Active
- 2018-08-03 MX MX2020001406A patent/MX2020001406A/es unknown
- 2018-08-03 FI FIEP18759209.2T patent/FI3661514T3/fi active
- 2018-08-03 HU HUE18759209A patent/HUE073047T2/hu unknown
- 2018-08-03 SG SG11202000549TA patent/SG11202000549TA/en unknown
- 2018-08-03 AU AU2018311974A patent/AU2018311974B2/en active Active
- 2018-08-03 IL IL322175A patent/IL322175A/en unknown
- 2018-08-03 SM SM20250413T patent/SMT202500413T1/it unknown
- 2018-08-03 TW TW107127110A patent/TWI907332B/zh active
- 2018-08-03 EP EP25196218.9A patent/EP4659806A3/en active Pending
- 2018-08-03 KR KR1020257024814A patent/KR20250116181A/ko active Pending
- 2018-08-03 MY MYPI2020000493A patent/MY208231A/en unknown
- 2018-08-03 WO PCT/US2018/045180 patent/WO2019028360A1/en not_active Ceased
- 2018-08-03 JP JP2020505487A patent/JP2020529996A/ja active Pending
- 2018-08-03 SI SI201831270T patent/SI3661514T1/sl unknown
- 2018-08-03 CN CN201880050881.4A patent/CN111182901A/zh active Pending
- 2018-08-03 CN CN202410743651.3A patent/CN118593507A/zh active Pending
- 2018-08-03 IL IL272300A patent/IL272300B2/en unknown
- 2018-08-03 DK DK18759209.2T patent/DK3661514T3/da active
- 2018-08-06 UY UY0001037834A patent/UY37834A/es not_active Application Discontinuation
-
2019
- 2019-03-26 US US16/364,322 patent/US20200054636A1/en not_active Abandoned
-
2020
- 2020-02-04 MX MX2024008096A patent/MX2024008096A/es unknown
- 2020-02-04 MX MX2024000348A patent/MX2024000348A/es unknown
-
2022
- 2022-03-23 US US17/701,863 patent/US20220226324A1/en not_active Abandoned
- 2022-06-16 US US17/842,389 patent/US20220313695A1/en not_active Abandoned
-
2023
- 2023-02-01 JP JP2023014110A patent/JP2023065372A/ja active Pending
-
2024
- 2024-06-07 AU AU2024203872A patent/AU2024203872A1/en active Pending
- 2024-09-06 US US18/827,049 patent/US20240423981A1/en not_active Abandoned
- 2024-11-01 JP JP2024192836A patent/JP2025020292A/ja active Pending
-
2025
- 2025-03-18 US US19/082,967 patent/US20250213565A1/en active Pending
- 2025-08-01 US US19/288,391 patent/US20260007671A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240423981A1 (en) | Treatment of hcm with pyrimidinedione compounds | |
| US20110166220A1 (en) | Dronedarone for the prevention of permanent atrial fibrillation | |
| CN102065855A (zh) | 决奈达隆在制备用于预防因心血管疾病住院或死亡的药物中的用途 | |
| KR20160095076A (ko) | 주요 부정적 심혈관 사건을 감소시키기 위한 조성물 및 방법 | |
| JP7620758B2 (ja) | 肺動脈性肺高血圧症の治療方法 | |
| HK40026724B (en) | Mavacamten for use in the treatment of hypertrophic cardiomyopathy | |
| HK40026724A (en) | Mavacamten for use in the treatment of hypertrophic cardiomyopathy | |
| CA2245095A1 (en) | Method for treating heart failure | |
| HK40028703A (zh) | 用於在肥厚型心肌病的治疗中使用的玛伐凯泰 | |
| US20250295639A1 (en) | Methods for treating heart diseases | |
| Singh et al. | Results: The results by analysis of varience revealed that wall thicknes opposite the site of infarction decreased from (mean±SD) 12.2±2.0 mm to 10.0±1.8 mm with coenzyme Q10 compared with 12.8±2.2 mm to 13.3+ 2.3 | |
| after Acute | Converting Enzyme in Patients | |
| US20130116586A1 (en) | Use of dronedarone or a pharmaceutically acceptable salt thereof for the preparation of a drug for the prevention of atrial fibrillation | |
| HK1156502A (en) | Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood |